【Company Recommendation】Emeishan Hongsen Biopharmaceutical Co., Ltd.

Company Introduction Emeishan Hongsen Biopharmaceutical Co., Ltd. is a national high-tech enterprise focusing on peptide fragments, protected amino acids, pharmaceutical intermediates, APIs, and CMO/CDMO fields. Business scope: an experienced project undertaking team escorts full life-cycle CMO/CDMO services; a GMP quality system that has been audited many times by domestic and foreign customers; the company has an independent technology R&D center, a provincial enterprise technology center, and Leshan Synthetic Biology Engineering Technology Research Center, providing one-stop services including process optimization, R&D, production, and sales. The company was established on February 18, 2011. It currently has more than 150 employees and more than 70 sets of various reactors ranging from 100L to 6300L, providing flexible and diversified cooperation models. Star Products 89030-95-5 Copper Peptide Copper peptide can effectively stimulate the biosynthesis of collagen in fibroblasts, thereby promoting rapid wound healing. It can also effectively block the neurotransmission of acetylcholine substances, thereby relaxing ...

• Source: drugdu
• 187
• June 26, 2026

China’s first ADC (Advanced Dioxide Doppler) to be submitted for market approval

On June 23, the CDE (Center for Drug Evaluation) website showed that Chia Tai Tianqing Pharmaceutical Group’s application for marketing authorization of vetectobactimab for injection was accepted. This monotherapy is indicated for patients with CLDN18.2-positive, locally advanced, or metastatic gastric/gastroesophageal junction adenocarcinoma who have received at least two lines of prior systemic therapy . Previously, this drug had been formally included in the CDE’s priority review and approval process . Screenshot source: CDE official website Vitacotobactam (development code: LM-302 ) is an antibody-drug conjugate (ADC) targeting Claudin18.2 (CLDN18.2) developed by Lixin Pharmaceuticals. It specifically binds to CLDN18.2-positive tumor cells, enters the cells via endocytosis, and releases small molecule toxins to achieve precise killing of tumor cells. In July 2025, China Biopharmaceutical announced that it would acquire 100% of Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. for a net consideration of approximately US$500 million , bringing the latter’s highly regarded bispecific antibody ...

• Source: drugdu
• 175
• June 25, 2026

Sanofi’s second autoimmune BTK inhibitor approved for marketing

On June 23, Sanofi announced that Tolebrutinib (trade name: Cenrifki) has been approved by the European Medicines Agency (EMA) for the treatment of relapse-free secondary progressive multiple sclerosis (SPMS). This drug is the first approved treatment for non-relapsing SPMS and Sanofi’s second approved autoimmune BTK inhibitor. Sanofi’s first autoimmune BTK inhibitor, Rilzabrutinib (trade name: Wayrilz ), was approved in the US and Europe in 2025.This approval was supported by the Phase III HERCULES study , which included 1131 patients with non-recurrent SPMS .Patients. Results showed that at a median follow-up of 133 weeks, the proportion of patients in the Tolebrutinib (60 mg, once daily) group who had confirmeddisability progression lasting at least 6 months was significantly lower than that inthe placebo group (22.6% vs 30.7%, HR=0.69, P=0.003).Multiple sclerosis (MS) is a chronic, immune-mediated neurodegenerative disease of the central nervous system that can lead to persistent and irreversible disability over time. ...

• Source: drugdu
• 161
• June 25, 2026

Qingfeng Pharmaceutical’s apalutamide tablets have been approved, adding another powerful tool to the field of anti-tumor therapy

According to the official website of the National Medical Products Administration (NMPA), the generic apalutamide tablets submitted by Kerui Pharmaceutical, a subsidiary of Qingfeng Pharmaceutical Group, were approved for production on May 19 and are considered to have passed the consistency evaluation. This is the third endocrine therapy chemical drug approved for Qingfeng Pharmaceutical, marking a new milestone in the company’s R&D and commercialization strategy in the field of prostate cancer treatment. 0 1 Apalutamide tablets: A new generation of androgen receptor inhibitors Blockbuster drugs for prostate cancer treatment Apalutamide is a new generation of oral, highly selective nonsteroidal androgen receptor (AR) inhibitors. It competitively blocks androgen binding by binding to the intracellular ligand-binding domain of AR with high affinity, inhibiting receptor conformational changes and nuclear translocation, and preventing AR translocation into the nucleus.¹ Simultaneously, it blocks the binding of AR to DNA response elements, inhibiting the transcription ...

• Source: drugdu
• 169
• June 25, 2026

Three Conversations We Heard Repeatedly at CPHI China 2026

Three days at CPHI China 2026 gave us the opportunity to meet pharmaceutical manufacturers, suppliers, buyers, and industry professionals from around the world. For Drugdu.com, exhibitions are not only about networking. They are also one of the best places to observe how the pharmaceutical industry is evolving and what companies are focusing on next. After hundreds of conversations across APIs, formulations, extracts, excipients, and pharmaceutical services, a few themes kept coming up. 1. Companies Are Looking for Their Next Growth Market One topic appeared repeatedly throughout the exhibition: Where should we focus next? Latin America. The Middle East. Southeast Asia. These regions were mentioned far more often than we expected. Many companies are no longer asking whether they should expand internationally. They are already active in global markets. The discussion has shifted toward market selection, resource allocation, and identifying the next region that offers sustainable growth. For many pharmaceutical companies, ...

• Source: drugdu
• 180
• June 20, 2026

On June 16, foreign media suddenly reported several pieces of news about semaglutide. One was that Novo Nordisk’s oral weight-loss drug Wegovy would soon be launched in China; another was that Novo Nordisk made it clear: regulatory data protection for semaglutide in China will last until the second quarter of 2027, when generics will be able to enter the market. According to foreign media reports, both pieces of news came from Novo Nordisk’s Global President and CEO, Mike Doustdar. In the past few days, Novo Nordisk’s global management has happened to be visiting China. On June 15, Health News reported that Lei Haichao, Director of the National Health Commission, met with several Novo Nordisk executives, to discuss Novo Nordisk’s presence in China and its future strategy. The two major pieces of news above were very likely leaked during this public event, drawing strong market attention. The news about oral semaglutide ...

• Source: drugdu
• 176
• June 17, 2026

World’s first! CSPC Group’s paclitaxel for injection (albumin-bound) (II) approved for marketing

  On June 15, CSPC Group’s paclitaxel for injection (albumin-bound) (II) (R&D code: SYHX2011) was approved for marketing by the National Medical Products Administration. This product is the world’s first fast-dissolving albumin-bound paclitaxel formulation, backed by independently developed innovative formulation and manufacturing processes, and has obtained patent authorizations in multiple countries including China, the U.S., and Europe. As a Class 2.2 modified new chemical drug, it represents a comprehensive upgrade in efficacy, safety, and clinical convenience, filling many of the clinical gaps of conventional albumin-bound paclitaxel, marking CSPC Group’s technological breakthrough in the field of antitumor nanomedicines and offering a better chemotherapy option for patients with advanced breast cancer. Figure 1. CSPC paclitaxel for injection (albumin-bound) (II) approved for marketing, source: NMPA website 01Breast Cancer and Taxanes Breast cancer is a highly prevalent malignant tumor in China. According to a report by the National Cancer Center of China, there were ...

• Source: drugdu
• 235
• June 17, 2026

Valuation of 7 billion yuan! Another large financing deal lands in the vaccine sector

On the evening of June 15, Fosun Pharma (600196) issued an official announcement that its vaccine platform, Fosun A&T, had completed a new round of capital increase and share expansion, issuing an additional 11.4954 million shares to four investors at a price of RMB 84.21 per share, raising a total of RMB 968 million and implying a pre-investment valuation of RMB 7 billion. This is a key capital move in Fosun A&T’s preparation for a Hong Kong IPO, and it has also injected important momentum into the R&D and commercialization of its vaccine pipeline.I. A star-studded investor lineup: Fosun leads the round, with China Resources and Chengdu state-owned capital joining in The investor mix in this capital increase is highly representative of the industry, underscoring the capital market’s long-term confidence in the vaccine sector: • Fosun Pharma Industry (controlling shareholder): Invested RMB 550 million to subscribe for 6.5315 million shares, ...

• Source: drugdu
• 162
• June 17, 2026

A world first! Coagulation Factor X activator – Bomitai enzyme α for injection (Bojia Ning) – conditionally approved for marketing!

On June 9, 2026, Jiangsu Beijietai Biotechnology Co., Ltd., a wholly-owned subsidiary of Shutaishan, received the Drug Registration Certificate for Bomitai Enzyme Alpha for Injection (trade name: Bojia Ning) issued by the National Medical Products Administration. This drug is a Class 1 therapeutic biological product manufactured domestically, with the approval number S20260040. This approval is conditional, and its indication is for the treatment of bleeding in adult patients with congenital hemophilia A or B whose factor VIII or IX inhibitors are >5 Bethesda units (BU). Hemophilia is an X-linked recessive inherited bleeding disorder, characterized by male onset and female carrier status. Hemophilia can be divided into hemophilia A and hemophilia B. Hemophilia A is characterized by a deficiency of clotting factor VIII (FVIII), while hemophilia B is characterized by a deficiency of clotting factor IX (FIX), both caused by mutations in the corresponding clotting factor genes. The clinical feature of ...

• Source: drugdu
• 195
• June 10, 2026

It’s here! Xanomeprazole Chloride Capsules (Kagero®) are now available, benefiting schizophrenia patients in China

On June 9th, Zai Lab’s first neurological product, Xanomelide Traxodium Chloride Capsules (Kagero® ) , was shipped from Suzhou and began supplying hospitals and pharmacies in multiple provinces and cities across China. On the same day, the drug was prescribed for the first time nationwide at Beijing Anding Hospital affiliated with Capital Medical University, and subsequently reached schizophrenia patients in over 30 cities and nearly 50 hospitals across the country. Ni Qian, member of the Party Working Committee and deputy director of the Management Committee of Suzhou Industrial Park, said: Zai Lab is a key witness to and participant in the booming development of the biopharmaceutical industry in the park. Ten of its innovative products, including Xanomeprazole and Traxolium chloride capsules , have been approved for marketing in China, demonstrating strong resilience and innovation capabilities. We will continue to support companies like Zai Lab, encouraging them to deepen their presence ...

• Source: drugdu
• 159
• June 10, 2026